bluebird bio (NASDAQ:BLUE) had its target price increased by equities researchers at SunTrust Banks to $232.00 in a report released on Thursday, The Fly reports. The firm presently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks’ price objective would indicate a potential upside of 32.76% from the stock’s current price.
Several other research firms have also weighed in on BLUE. Cantor Fitzgerald reduced their price target on shares of bluebird bio from $122.00 to $113.00 and set an “underweight” rating for the company in a research report on Thursday, February 22nd. ValuEngine upgraded shares of bluebird bio from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. Morgan Stanley increased their target price on shares of bluebird bio from $152.00 to $209.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 21st. Finally, William Blair initiated coverage on shares of bluebird bio in a research report on Monday, March 5th. They set an “outperform” rating and a $242.00 target price for the company. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. bluebird bio presently has an average rating of “Hold” and an average target price of $195.65.
BLUE opened at $174.75 on Thursday. The stock has a market cap of $8,549.68, a P/E ratio of -22.67 and a beta of 2.16. bluebird bio has a fifty-two week low of $74.45 and a fifty-two week high of $236.17.
In other news, COO Susanna Gatti High sold 17,262 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $195.91, for a total value of $3,381,798.42. Following the sale, the chief operating officer now directly owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Davidson sold 4,000 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 79,512 shares of company stock worth $15,051,218. Insiders own 3.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in BLUE. Meeder Asset Management Inc. lifted its holdings in shares of bluebird bio by 2,110.3% in the fourth quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after buying an additional 612 shares in the last quarter. NuWave Investment Management LLC purchased a new stake in shares of bluebird bio in the fourth quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after buying an additional 813 shares in the last quarter. D.A. Davidson & CO. purchased a new stake in shares of bluebird bio in the fourth quarter worth about $214,000. Finally, Quinn Opportunity Partners LLC purchased a new stake in shares of bluebird bio in the fourth quarter worth about $232,000.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/04/19/bluebird-bio-blue-pt-raised-to-232-00-at-suntrust-banks.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.